Author: Tony Proctor, Emerald Clinical Trials Chief Financial Officer China’s biotech surge…
China’s Oncology Paradigm Shift: From Proof-of-Concept to FDA Registration Pathway — EXECUTIVE…
The 63rd ERA Congress, held June 3–6, 2026 in Glasgow, reinforced a…
Posts Authors:Jonathan Barratt, PhD, FRCP. The Mayer Professor of Renal Medicine, University…
How CRO selection significantly influences study outcomes By Luke Gill and Claudio…
SINGAPORE – March 12, 2026 Emerald Clinical Trials, a leading global clinical…
By Claudio Hegenberger, MD and Johannes Wolff, MD, PhD In the current…
Colin Orford is an experienced drug developer with 33 years of experience…
Insights from IIgANN 2025 in Prague: Advancing the Science and Shaping the Future of IgA Nephropathy
Chris Christodoulou, Senior Manager, Scientific and Medical Affairs The IIgANN 2025 Symposium,…